share_log

Frank T. Watkins Sells 3,000 Shares of ShockWave Medical, Inc. (NASDAQ:SWAV) Stock

Frank T. Watkins Sells 3,000 Shares of ShockWave Medical, Inc. (NASDAQ:SWAV) Stock

弗蘭克·T·沃特金斯出售3,000股衝擊波醫療公司(納斯達克代碼:SWAV)股票
Defense World ·  2022/09/23 05:12

ShockWave Medical, Inc. (NASDAQ:SWAV – Get Rating) Director Frank T. Watkins sold 3,000 shares of the firm's stock in a transaction dated Tuesday, September 20th. The shares were sold at an average price of $290.09, for a total transaction of $870,270.00. Following the completion of the sale, the director now owns 9,796 shares of the company's stock, valued at $2,841,721.64. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

衝擊波醫療公司(納斯達克代碼:SWAVGET評級)董事弗蘭克·T·沃特金斯在一筆日期為9月20日(星期二)的交易中出售了3,000股該公司股票。這些股票以290.09美元的平均價格出售,總成交金額為870,270.00美元。出售完成後,董事現在擁有9,796股該公司股票,價值2,841,721.64美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過此超鏈接.

ShockWave Medical Stock Down 9.1 %

衝擊波醫療類股下跌9.1%

Shares of SWAV opened at $258.84 on Friday. The firm's 50 day moving average is $263.66 and its 200-day moving average is $208.21. The stock has a market capitalization of $9.26 billion, a PE ratio of 177.29 and a beta of 1.06. The company has a current ratio of 5.32, a quick ratio of 4.41 and a debt-to-equity ratio of 0.02. ShockWave Medical, Inc. has a 12 month low of $113.36 and a 12 month high of $314.90.

上週五,西南航空的股價開盤報258.84美元。該公司的50日移動均線切入位在263.66美元,200日移動均線切入位在208.21美元。該股市值為92.6億美元,市盈率為177.29,貝塔係數為1.06.該公司的流動比率為5.32,速動比率為4.41,債務權益比率為0.02。Shockwave Medical,Inc.的12個月低點為113.36美元,12個月高位為314.90美元。

Get
到達
ShockWave Medical
衝擊波醫療
alerts:
警報:

ShockWave Medical (NASDAQ:SWAV – Get Rating) last announced its quarterly earnings data on Monday, August 8th. The company reported $0.68 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.43 by $0.25. The business had revenue of $120.70 million for the quarter, compared to analysts' expectations of $107.51 million. ShockWave Medical had a net margin of 15.11% and a return on equity of 21.25%. The firm's quarterly revenue was up 115.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.01) earnings per share. Equities research analysts forecast that ShockWave Medical, Inc. will post 2.57 EPS for the current year.

衝擊波醫療(納斯達克:SWAV-GET評級)上一次公佈季度收益數據是在8月8日(星期一)。該公司公佈本季度每股收益(EPS)為0.68美元,高於分析師普遍預期的0.43美元和0.25美元。該業務當季營收為1.207億美元,高於分析師預期的1.0751億美元。Shockwave Medical的淨利潤率為15.11%,股本回報率為21.25%。該公司的季度收入與去年同期相比增長了115.5%。去年同期,該公司公佈的每股收益為0.01美元。股票研究分析師預測,Shockwave Medical,Inc.本年度每股收益將達到2.57美元。

Analysts Set New Price Targets

分析師設定新的價格目標

Several brokerages have issued reports on SWAV. Oppenheimer downgraded shares of ShockWave Medical from a "market perform" rating to an "underperform" rating and set a $165.00 price objective for the company. in a research report on Tuesday, September 6th. Morgan Stanley raised their price objective on shares of ShockWave Medical from $201.00 to $255.00 and gave the stock an "equal weight" rating in a research report on Tuesday, August 9th. Piper Sandler raised their price objective on shares of ShockWave Medical from $278.00 to $338.00 and gave the stock an "overweight" rating in a research report on Monday, August 29th. Wells Fargo & Company raised their price objective on shares of ShockWave Medical from $176.00 to $255.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 9th. Finally, Canaccord Genuity Group raised their price objective on shares of ShockWave Medical from $232.00 to $256.00 and gave the stock a "buy" rating in a research report on Tuesday, August 9th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, ShockWave Medical presently has a consensus rating of "Moderate Buy" and an average price target of $246.50.
幾家券商已經發布了關於SWAV的報告。奧本海默將Shockwave Medical的股票評級從“市場表現”下調至“表現不佳”,併為該公司設定了165.00美元的目標價。在9月6日星期二的一份研究報告中。8月9日,摩根士丹利在一份研究報告中將衝擊波醫療的股票目標價從201.00美元上調至255.00美元,並給予該股“同等權重”的評級。8月29日,派珀·桑德勒在一份研究報告中將Shockwave Medical的股票目標價從278.00美元上調至338.00美元,並給予該股“增持”評級。富國銀行將Shockwave Medical的股票目標價從176.00美元上調至255.00美元,並在8月9日(星期二)的一份研究報告中給予該股“增持”評級。最後,Cancord Genuity Group在8月9日(星期二)的一份研究報告中將Shockwave Medical的股票目標價從232.00美元上調至256.00美元,並給予該股“買入”評級。一名投資分析師對該股的評級為賣出,一名分析師給出了持有評級,七名分析師給出了該公司股票的買入評級。根據MarketBeat的數據,Shockwave Medical目前的共識評級為“中等買入”,平均目標價為246.50美元。

Institutional Inflows and Outflows

機構資金流入和流出

Hedge funds have recently added to or reduced their stakes in the company. Rockefeller Capital Management L.P. increased its stake in ShockWave Medical by 104.9% in the fourth quarter. Rockefeller Capital Management L.P. now owns 166 shares of the company's stock valued at $29,000 after acquiring an additional 85 shares during the last quarter. CWM LLC grew its stake in shares of ShockWave Medical by 219.7% during the second quarter. CWM LLC now owns 195 shares of the company's stock worth $37,000 after buying an additional 134 shares during the last quarter. AdvisorShares Investments LLC bought a new stake in shares of ShockWave Medical during the first quarter worth $40,000. PenderFund Capital Management Ltd. bought a new stake in shares of ShockWave Medical during the first quarter worth $41,000. Finally, First Horizon Advisors Inc. grew its stake in shares of ShockWave Medical by 3,666.7% during the second quarter. First Horizon Advisors Inc. now owns 226 shares of the company's stock worth $43,000 after buying an additional 220 shares during the last quarter. 95.40% of the stock is owned by institutional investors.

對衝基金最近增持或減持了該公司的股份。洛克菲勒資本管理公司在第四季度增持了Shockwave Medical的股份104.9%。洛克菲勒資本管理公司在上個季度增持了85股股票後,現在擁有166股該公司股票,價值2.9萬美元。第二季度,Cwm LLC在Shockwave Medical的持股增加了219.7%。Cwm LLC現在持有195股該公司股票,價值3.7萬美元,在上個季度又購買了134股。AdvisorShares Investments LLC在第一季度購買了ShockWave Medical價值4萬美元的新股。PenderFund Capital Management Ltd.在第一季度購買了Shockwave Medical價值41,000美元的新股。最後,First Horizon Advisors Inc.在第二季度增持了Shockwave Medical的股份3,666.7%。First Horizon Advisors Inc.現在持有226股該公司股票,價值43,000美元,該公司在上個季度又購買了220股。95.40%的股票由機構投資者持有。

About ShockWave Medical

關於衝擊波醫療

(Get Rating)

(獲取評級)

ShockWave Medical, Inc, a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD.

Shockwave Medical,Inc.是一家醫療設備公司,致力於開發和商業化血管內碎石技術,用於治療全球外周血管、冠狀動脈和心臟瓣膜疾病患者的鈣化斑塊。該公司提供用於治療膝關節以上外周動脈疾病(PAD)的M5導管;用於治療冠狀動脈疾病的C2導管;以及用於治療膝蓋以下PAD的S4導管。

Read More

閲讀更多內容

  • Get a free copy of the StockNews.com research report on ShockWave Medical (SWAV)
  • What Steelcase's Earnings Say About the Return to the Office?
  • The Institutions Hold On To Darden Restaurants International
  • Is The Golden Age Of Homebuilding Already Over?
  • These 3 Big Dividend Payers Also Boast Strong Price Growth
  • Natural Gas Prices Continue To Rally, These Stocks Should Benefit
  • 免費獲取StockNews.com關於Shockwave Medical(SWAV)的研究報告
  • 斯蒂爾凱斯的收益説明瞭他重返辦公室的原因嗎?
  • 這些機構持有達頓餐飲國際公司的股份
  • 住房建設的黃金時代已經結束了嗎?
  • 這三大股利支付者也擁有強勁的價格增長
  • 天然氣價格繼續回升,這些股票應該會受益

Receive News & Ratings for ShockWave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ShockWave Medical and related companies with MarketBeat.com's FREE daily email newsletter.

接受《衝擊波醫學日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對ShockWave Medical和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論